DaVita price target raised to $136 from $114 at Deutsche Bank Deutsche Bank raised its price target for DaVita to reflect its 2014 estimates and calls the company its top pick within Health Care Providers. The firm reiterates a Buy rating on the name.
DaVita Kidney Care finalizes DOJ Settlement DaVita Kidney Care, a division of DaVita HealthCare Partners announced it has finalized its comprehensive settlement with the U.S. Department of Justice, or DOJ, and certain other federal agencies regarding allegations of improperly structured joint ventures with certain physician partners. As announced in February, DaVita Kidney Care will be subject to a Corporate Integrity Agreement and an independent monitor to oversee certain future joint ventures. The agreement also includes a repayment to the government and a provision requiring executive certification of quarterly and annual compliance reports.